AIO-Studien-gGmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Established: 2007-01-01

Employees: 11

Market Cap: -

Website: http://www.aio-studien-ggmbh.de

Clinical Trials

Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Phase 3

Recruiting

Conditions: Renal Cell Cancer, Recurrent
Renal Cell Carcinoma, Metastatic

Interventions: Behavioral: Concomitant coaching

First Posted Date: 2017-01-09

Last Posted Date: 2023-06-15

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 430

Registration Number: NCT03013946

Locations: 🇩🇪
BAG Onkologische Gemeinschaftspraxis, Dresden, Germany
🇩🇪
Krankenhaus Barmherzige Brüder Trier, Trier, Rheinland-Pfalz, Germany
🇩🇪
FEK - Friedrich-Ebert-Krankenhaus Neumünster, Neumünster, Schleswig-Holstein, Germany

and more 31 locations

Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control

Phase 2

Terminated

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Sunitinib
Drug: Nivolumab
Drug: Pazopanib

First Posted Date: 2016-11-09

Last Posted Date: 2021-09-08

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 49

Registration Number: NCT02959554

Locations: 🇩🇪
Universitätsklinikum Essen (AöR) - Klinik und Poliklinik für Urologie / Kinderurologie und Uroonkologie, Essen, Germany
🇦🇹
Medizinische Universität Wien - Universitätsklinik für Innere Medizin I, Klinische Abteilung für Onkologie, Wien, Austria

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma

Phase 2

Completed

Conditions: Carcinoma, Renal Cell
Clear-cell Metastatic Renal Cell Carcinoma

Interventions: Biological: Nivolumab/Ipilimumab

First Posted Date: 2016-09-28

Last Posted Date: 2022-10-06

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 200

Registration Number: NCT02917772

Locations: 🇫🇷
CHD Vendée, La Roche-Sur-Yon, France
🇧🇪
ZNA Middelheim, Antwerpen, Belgium
🇨🇿
Fakultní nemocnice Hradec Králové, Hradec Králové, Czechia

and more 32 locations

Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients

Phase 4

Completed

Conditions: Adenocarcinoma Pancreas

Interventions: Drug: Nab-paclitaxel
Other: Best Supportive Care
Drug: Gemcitabine

First Posted Date: 2016-06-24

Last Posted Date: 2021-08-10

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 32

Registration Number: NCT02812992

Locations: 🇩🇪
Universitätsklinikum Mannheim II. Medizinische Klinik, Mannheim, Germany

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Recruiting

Conditions: Metastatic Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer Stage II
Non Small Cell Lung Cancer Stage III
Non-small Cell Lung Cancer Metastatic
Small-cell Lung Cancer
Non-small Cell Lung Cancer Stage I

Interventions: Other: data collection

First Posted Date: 2015-12-04

Last Posted Date: 2024-02-06

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 12400

Registration Number: NCT02622581

Locations: 🇩🇪
Pius-Hospital, Oldenburg, Germany

Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients

Phase 3

Terminated

Conditions: Cancer
Venous Thromboembolism

Interventions: Drug: Rivaroxaban
Drug: low-molecular heparine

First Posted Date: 2015-10-22

Last Posted Date: 2021-05-03

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 246

Registration Number: NCT02583191

Locations: 🇩🇪
Uniklinik, Aachen, Germany

Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)

Phase 2

Terminated

Conditions: Metastatic Squamous Non-small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: Pembrolizumab

First Posted Date: 2015-09-30

Last Posted Date: 2022-01-04

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 41

Registration Number: NCT02564380

Locations: 🇩🇪
LungenClinic Grosshansdorf, Großhansdorf, Germany

First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine

Phase 2

Completed

Conditions: Metastatic Pancreatic Cancer
Adenocarcinoma of the Pancreas

Interventions: Drug: nab-paclitaxel and gemcitabine
Drug: gemcitabine mono and nab-paclitaxel and gemcitabine

First Posted Date: 2015-09-30

Last Posted Date: 2022-11-22

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 325

Registration Number: NCT02564146

Locations: 🇩🇪
Kliniken Nordoberpfalz AG, Klinikum Weiden, Weiden, Germany

Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction

Phase 1

Completed

Conditions: Adenocarcinoma,Stomach
Adenocarcinoma, Esophagogastric Junction

Interventions: Drug: S-1

First Posted Date: 2015-09-30

Last Posted Date: 2021-04-29

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 30

Registration Number: NCT02564367

Locations: 🇩🇪
Klinikum der Universität München, Campus Großhadern, München, Bayern, Germany

Maintaining ERBB Blockade in EGFR-mutated Lung Cancer

Phase 2

Terminated

Conditions: Non-small-cell Lung Cancer With Somatic EGFR Mutations

Interventions: Drug: Pemetrexed
Drug: Afatinib

First Posted Date: 2015-07-02

Last Posted Date: 2018-01-09

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 4

Registration Number: NCT02488694

Locations: 🇩🇪
Universitätsklinikum Essen, Essen, Germany

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy